Atopic Dermatitis Therapeutics Market Size, Industry Analysis Report, Regional Outlook, Competitive Landscape & Forecast, 2021 – 2027

Atopic Dermatitis Therapeutic Market size is projected to experience significant growth from 2018 to 2024.
 

Atopic dermatitis therapeutic market is expected to witness significant growth due to rising cases of Atopic dermatitis with the increase in prevalence of food allergies exacerbating Atopic Dermatitis. Escalation in consumption of chicken eggs, cow’s milk, peanuts, wheat, nuts, soy and fish increase the chances of developing food allergies that result in development of atopic dermatitis. Globally, around one-third of the children with atopic dermatitis are diagnosed with food allergy.
 

Introduction of the emerging therapies such as baricitinib (Eli Lilly and Company), Tralokinumab (LEO Pharma), Furestem (Kangstem Biotech), and other therapies is expected to fuel market growth in upcoming years. Robust pipeline, advancement in treatment, growing government and pharmaceutical companies’ initiatives for the development of the novel therapies for atopic dermatitis will result in business expansion. Immense need to develop novel therapies for severe recalcitrant patients that do not respond to the existing therapies is the major reason behind extensive molecule in development pipeline.
 

Factors such as lack of awareness regarding the treatment and diagnosis, patent expiry of marketed drugs, challenges in performing clinical trials, genericization of the existing drugs and poor patient adherence of marketed drugs are hindering the market growth.
 

Increasing use of conventional systemic immunosuppressants such as azathioprine and cyclosporine that are largely used for the treating moderate to severe patients will boost the product demand. Therefore, systemic immunosuppressants business is expected to witness the significant growth during forecasted period. Approval of novel therapies such as Phosphodiesterase-4 (PDE-4) Inhibitors i.e. Eucrisa (crisaborole) in 2016 and Interleukin Inhibitor-4/ Interleukin Inhibitor-13 (IL-4/IL-13) in 2017 has changed the treatment landscape of atopic dermatitis.
 

The market for topical route of administration products holds larger market share compared to the oral and injectable products owning to the advantages of topical products such as high patience adherence, cost effectiveness.
 

U.S. atopic dermatitis market is the largest market in North America as well as in the world’ owing to high prevalence of food and skin allergies, and high prevalence of atopic dermatitis. Also, other factors such as adoption of novel medications, better reimbursement policies and launch of the maximum number of drugs U.S. augment market expansion.
 

Asia Pacific atopic dermatitis market should grow with an explosive rate due to increasing healthcare expenditure, improving healthcare infrastructure and awareness. Moreover, growing need to address lifestyle induced disorders will play a productive role in introducing atopic dermatitis therapies during the forecast period.
 

Some of the key industry players include Regeneron Pharmaceuticals Inc, Eli Lilly and Company, LEO Pharma A/S, Glaxosmithkline plc, Novartis AG, Kang Stem Biotech Co., Ltd, Sanofi S.A and others. Among these players, Eli Lilly and Company, LEO Pharma, Kang Stem Biotech Co., Ltd., Glaxosmithkline plc and others are focusing on developing novel therapies for the treatment of Atopic Dermatitis. In January 2018, Regeneron Pharmaceuticals, Inc and Sanofi had accelerated and expanded the investment for the clinical development of the Dupilumab for atopic dermatitis.
 

Atopic Dermatitis Market by product, 2013-2024 (USD Million)

• Anti-inflammatory agents
  • Corticosteroids
  • Calcineurin Inhibitors 
• Antihistamines
• Interleukin Inhibitors
• Phosphodiesterase-4 (PDE-4) Inhibitors
• Antibiotics
• Immunosuppressants
• Others

Atopic Dermatitis Market by Route of Administration, 2013-2024 (USD Million)

• Topical
• Oral
• Injectable

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
• Latin America
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa

Company Profiles:

• Novartis AG
• Pfizer
• Connetics Corporation
• Regeneron Pharmaceuticals Inc.
• Fujisawa Healthcare
• Eli Lilly and Company
• LEO Pharma A/S
• Kang Stem Biotech Co., Ltd.
• Glaxosmithkline plc
• Sanofi S.A
• Others

What Information does this report contain?